Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Post by zenvestingon Sep 01, 2015 4:16pm
122 Views
Post# 24069592

Molnlycke not meeting minimums

Molnlycke not meeting minimums"Molnlycke informed Covalon that Molnlycke does not anticipate being able to meet the annual minimum sales commitment under the license agreement by the anniversary of November 1, 2015. On August 17, 2015, Molnlycke informed Covalon that Molnlycke wishes to terminate the license and distribution agreements. Covalon and Molnlycke are in discussions about the terms and conditions of termination of the agreements." Some might think this is a negative, but in light of our recent sales gains from Covalon's expanded product line to their expanding distribution network.....I think Covalon's sales organization might beble to do better for IVClear and SurgiClear, not to mention the possibility of finding a stronger partner who might be interested in it.
Bullboard Posts